Lotifazole

Lotifazole

SCHEMBL286772

O=C(Nc1nc(-c2ccccc2)cs1)OCC(Cl)(Cl)Cl

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELOVL1 Q9BW60 1/20 0.56
MAPT P10636 3/20 0.55
ADORA3 P0DMS8 1/20 0.55
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
CASP3 P42574 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
PARP1 P09874 2/20 0.55
PKM P14618 1/20 0.55
GSTO1 P78417 1/20 0.54
ALDH1A1 P00352 1/20 0.53
HDAC3 O15379 1/20 0.53
HDAC4 P56524 1/20 0.53
HDAC1 Q13547 1/20 0.53
HDAC7 Q8WUI4 1/20 0.53
HDAC2 Q92769 1/20 0.53
HDAC10 Q969S8 1/20 0.53
HDAC11 Q96DB2 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11241744 0.90 ROCK1 (0.54) MAPTPARP1ALDH1A1MEN1KMT2A
SCHEMBL11322732 0.89 ABL1 (0.61) MAPTNPC1RAB9AGSTO1ALDH1A1
SCHEMBL10962623 0.88 ROCK1 (0.50) ELOVL1MAPTNPC1RAB9ACASP3
SCHEMBL10965935 0.86 HDAC3 (0.57) MAPTNPC1RAB9AGSTO1ALDH1A1
SCHEMBL10964259 0.85 MAPT (0.47) MAPTNPC1RAB9ACASP3SENP7
SCHEMBL10964529 0.84 RAB9A (0.57) MAPTNPC1RAB9ACASP3SENP7
SCHEMBL10962710 0.84 RAB9A (0.63) MAPTNPC1RAB9AALDH1A1MEN1
SCHEMBL10962624 0.84 KMT2A (0.63) MAPTRAB9AALDH1A1HDAC3HDAC4
SCHEMBL10965959 0.84 CFTR (0.49) MAPTNPC1RAB9APARP1PKM
SCHEMBL10963204 0.83 MAPT (0.47) MAPTNPC1RAB9APKMGSTO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 587 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120183600-A1 NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS CHEN CHIEN-HUNG (US) 2012-07-19 US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
EP-0001727-B1 NEW DERIVATIVES OF 4-PHENYL-2-(2',2',2-TRICHLORETHOXYCARBOXAMIDO)-THIAZOLE USEFUL AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THE PREPARATION OF THESE COMPOUNDS PIERRE FABRE S.A. (FR) 1981-11-11 EP claimed
US-4225610-A TREATMENT OF RHEUMATOID ARTHRITIS PIERRE FABRE, S.A. (FR) 1980-09-30 US claimed
US-20250304667-A1 COMPLEMENT COMPONENT C5 ANTIBODIES ALLERGAN INC (US) 2025-10-02 US disclosed
EP-3693381-B1 LIGAND BINDING MOLECULES AND USES THEREOF VEGENICS PTY LTD (AU) 2025-09-03 EP disclosed
US-20250161402-A1 THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE SCHEPENS EYE RES INST (US) 2025-05-22 US disclosed
US-20240301370-A1 Ligand Binding Molecules and Uses Thereof VEGENICS PTY LIMITED (AU) 2024-09-12 US disclosed
US-20240294652-A1 IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS AMGEN K-A, INC. 2024-09-05 US disclosed
US-20240279317-A1 COMPLEMENT COMPONENT C5 ANTIBODIES ALLERGAN INC (US) 2024-08-22 US disclosed
US-11866739-B2 Ligand binding molecules and uses thereof VEGENICS PTY LIMITED (AU) 2024-01-09 US disclosed
US-11858999-B2 IL-17 receptor A antigen binding proteins AMGEN K-A, INC. (US) 2024-01-02 US disclosed
EP-0140709-A2 5-Lipoxygenase inhibitors MERCK FROSST CANADA INC. (CA) 1985-05-08 EP disclosed
EP-0138481-A2 Leukotriene biosynthesis inhibitors MERCK FROSST CANADA INC. (CA) 1985-04-24 EP disclosed
EP-0136893-A2 Benzo[a]phenothiazines and hydro-derivatives and pharmaceutical compositions containing them MERCK FROSST CANADA INC. (CA) 1985-04-10 EP disclosed
EP-0123543-A1 Leukotriene antagonists, their production and use and compositions containing them MERCK FROSST CANADA INC. (CA) 1984-10-31 EP disclosed
EP-0123541-A1 Leukotriene antagonists MERCK FROSST CANADA INC. (CA) 1984-10-31 EP disclosed
EP-0001727-B1 NEW DERIVATIVES OF 4-PHENYL-2-(2',2',2-TRICHLORETHOXYCARBOXAMIDO)-THIAZOLE USEFUL AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THE PREPARATION OF THESE COMPOUNDS PIERRE FABRE S.A. (FR) 1981-11-11 EP disclosed
US-4225610-A TREATMENT OF RHEUMATOID ARTHRITIS PIERRE FABRE, S.A. (FR) 1980-09-30 US disclosed
EP-0001727-A2 New derivatives of 4-phenyl-2-(2',2',2-trichlorethoxycarboxamido)-thiazole useful as medicaments, pharmaceutical compositions containing them and process for the preparation of these compounds PIERRE FABRE S.A. (FR) 1979-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11858999-B2 IL-17 receptor A antigen binding proteins IL17A, IL23R, IL15RA ELOVL1 4140/4885MAPT 2416/4885ADORA3 643/4885
US-20250161402-A1 THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE CRYAB, CRYAA, FUCA2 ELOVL1 329/4885MAPT 1403/4885ADORA3 3693/4885
US-20240294652-A1 IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS IL17A, IL23R, IL15RA ELOVL1 4140/4885MAPT 2416/4885ADORA3 643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.